The Rationale for Selective Laser Trabeculoplasty in Africa

Tony Realini, Olusola Olawoye, Nkiru Kizor-Akaraiwe, Selina Manji, Arthur J Sit

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Glaucoma is the leading cause of irreversible blindness in Africa. The condition is treatable but not curable. There are numerous obstacles to glaucoma care in Africa, including availability, accessibility and affordability of treatments, as well as medication nonadherence among patients. Medical therapy is costly relative to the average income in Africa and it requires daily self-dosing by patients. Surgery is of limited availability in many regions in Africa, and a high proportion of patients refuse surgery because it is expensive. Selective laser trabeculoplasty (SLT) proves to be a favorable alternative to medical or surgical care, as it is highly effective and safe in people of African descent, more cost-effective than medical therapy, quick and easy to perform, and portable. The procedure also requires no postoperative care, thus obviates the issue of nonadherence. In uncontrolled studies, SLT has a high response rate and it lowers intraocular pressure by 30% to 40%, which exceeds the goal in international guidelines for initial therapies. The African Glaucoma Consortium (AGC), a member-driven stakeholder collective, has been formed in part to develop the infrastructure for continent-wide improvements in glaucoma care. It embraces SLT as a potential key tool in their development plans. The mission of AGC includes improving clinical care by educating existing and new health care professionals to expand the provider network, by conducting trials to identify optimal care strategies for glaucoma in Africa, and by facilitating the development of an integrated network of Centers of Excellence to bring SLT and other crucial glaucoma therapies to communities throughout Africa.

Original languageEnglish (US)
Pages (from-to)387-393
Number of pages7
JournalAsia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Volume7
Issue number6
DOIs
StatePublished - Nov 1 2018

Fingerprint

Trabeculectomy
Glaucoma
Lasers
Therapeutics
Medication Adherence
Postoperative Care
Blindness
Intraocular Pressure
Guidelines
Delivery of Health Care
Costs and Cost Analysis

Keywords

  • Africa
  • glaucoma
  • selective laser trabeculoplasty

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The Rationale for Selective Laser Trabeculoplasty in Africa. / Realini, Tony; Olawoye, Olusola; Kizor-Akaraiwe, Nkiru; Manji, Selina; Sit, Arthur J.

In: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), Vol. 7, No. 6, 01.11.2018, p. 387-393.

Research output: Contribution to journalReview article

Realini, Tony ; Olawoye, Olusola ; Kizor-Akaraiwe, Nkiru ; Manji, Selina ; Sit, Arthur J. / The Rationale for Selective Laser Trabeculoplasty in Africa. In: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2018 ; Vol. 7, No. 6. pp. 387-393.
@article{59b980986e924891836de22156b0c895,
title = "The Rationale for Selective Laser Trabeculoplasty in Africa",
abstract = "Glaucoma is the leading cause of irreversible blindness in Africa. The condition is treatable but not curable. There are numerous obstacles to glaucoma care in Africa, including availability, accessibility and affordability of treatments, as well as medication nonadherence among patients. Medical therapy is costly relative to the average income in Africa and it requires daily self-dosing by patients. Surgery is of limited availability in many regions in Africa, and a high proportion of patients refuse surgery because it is expensive. Selective laser trabeculoplasty (SLT) proves to be a favorable alternative to medical or surgical care, as it is highly effective and safe in people of African descent, more cost-effective than medical therapy, quick and easy to perform, and portable. The procedure also requires no postoperative care, thus obviates the issue of nonadherence. In uncontrolled studies, SLT has a high response rate and it lowers intraocular pressure by 30{\%} to 40{\%}, which exceeds the goal in international guidelines for initial therapies. The African Glaucoma Consortium (AGC), a member-driven stakeholder collective, has been formed in part to develop the infrastructure for continent-wide improvements in glaucoma care. It embraces SLT as a potential key tool in their development plans. The mission of AGC includes improving clinical care by educating existing and new health care professionals to expand the provider network, by conducting trials to identify optimal care strategies for glaucoma in Africa, and by facilitating the development of an integrated network of Centers of Excellence to bring SLT and other crucial glaucoma therapies to communities throughout Africa.",
keywords = "Africa, glaucoma, selective laser trabeculoplasty",
author = "Tony Realini and Olusola Olawoye and Nkiru Kizor-Akaraiwe and Selina Manji and Sit, {Arthur J}",
year = "2018",
month = "11",
day = "1",
doi = "10.22608/APO.2018271",
language = "English (US)",
volume = "7",
pages = "387--393",
journal = "Asia-Pacific Journal of Ophthalmology",
issn = "2162-0989",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The Rationale for Selective Laser Trabeculoplasty in Africa

AU - Realini, Tony

AU - Olawoye, Olusola

AU - Kizor-Akaraiwe, Nkiru

AU - Manji, Selina

AU - Sit, Arthur J

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Glaucoma is the leading cause of irreversible blindness in Africa. The condition is treatable but not curable. There are numerous obstacles to glaucoma care in Africa, including availability, accessibility and affordability of treatments, as well as medication nonadherence among patients. Medical therapy is costly relative to the average income in Africa and it requires daily self-dosing by patients. Surgery is of limited availability in many regions in Africa, and a high proportion of patients refuse surgery because it is expensive. Selective laser trabeculoplasty (SLT) proves to be a favorable alternative to medical or surgical care, as it is highly effective and safe in people of African descent, more cost-effective than medical therapy, quick and easy to perform, and portable. The procedure also requires no postoperative care, thus obviates the issue of nonadherence. In uncontrolled studies, SLT has a high response rate and it lowers intraocular pressure by 30% to 40%, which exceeds the goal in international guidelines for initial therapies. The African Glaucoma Consortium (AGC), a member-driven stakeholder collective, has been formed in part to develop the infrastructure for continent-wide improvements in glaucoma care. It embraces SLT as a potential key tool in their development plans. The mission of AGC includes improving clinical care by educating existing and new health care professionals to expand the provider network, by conducting trials to identify optimal care strategies for glaucoma in Africa, and by facilitating the development of an integrated network of Centers of Excellence to bring SLT and other crucial glaucoma therapies to communities throughout Africa.

AB - Glaucoma is the leading cause of irreversible blindness in Africa. The condition is treatable but not curable. There are numerous obstacles to glaucoma care in Africa, including availability, accessibility and affordability of treatments, as well as medication nonadherence among patients. Medical therapy is costly relative to the average income in Africa and it requires daily self-dosing by patients. Surgery is of limited availability in many regions in Africa, and a high proportion of patients refuse surgery because it is expensive. Selective laser trabeculoplasty (SLT) proves to be a favorable alternative to medical or surgical care, as it is highly effective and safe in people of African descent, more cost-effective than medical therapy, quick and easy to perform, and portable. The procedure also requires no postoperative care, thus obviates the issue of nonadherence. In uncontrolled studies, SLT has a high response rate and it lowers intraocular pressure by 30% to 40%, which exceeds the goal in international guidelines for initial therapies. The African Glaucoma Consortium (AGC), a member-driven stakeholder collective, has been formed in part to develop the infrastructure for continent-wide improvements in glaucoma care. It embraces SLT as a potential key tool in their development plans. The mission of AGC includes improving clinical care by educating existing and new health care professionals to expand the provider network, by conducting trials to identify optimal care strategies for glaucoma in Africa, and by facilitating the development of an integrated network of Centers of Excellence to bring SLT and other crucial glaucoma therapies to communities throughout Africa.

KW - Africa

KW - glaucoma

KW - selective laser trabeculoplasty

UR - http://www.scopus.com/inward/record.url?scp=85058917047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058917047&partnerID=8YFLogxK

U2 - 10.22608/APO.2018271

DO - 10.22608/APO.2018271

M3 - Review article

C2 - 30484574

AN - SCOPUS:85058917047

VL - 7

SP - 387

EP - 393

JO - Asia-Pacific Journal of Ophthalmology

JF - Asia-Pacific Journal of Ophthalmology

SN - 2162-0989

IS - 6

ER -